Hennion & Walsh Asset Management Inc. Purchases 26,828 Shares of Urogen Pharma $URGN

Hennion & Walsh Asset Management Inc. raised its position in shares of Urogen Pharma (NASDAQ:URGN) by 69.9% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 65,183 shares of the company’s stock after purchasing an additional 26,828 shares during the quarter. Hennion & Walsh Asset Management Inc. owned 0.14% of Urogen Pharma worth $1,300,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Osaic Holdings Inc. grew its holdings in shares of Urogen Pharma by 491.2% during the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the last quarter. CWM LLC boosted its stake in Urogen Pharma by 18.0% during the 3rd quarter. CWM LLC now owns 4,271 shares of the company’s stock valued at $85,000 after purchasing an additional 650 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Urogen Pharma by 422.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after purchasing an additional 5,571 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Urogen Pharma by 9.4% in the second quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock worth $127,000 after purchasing an additional 797 shares during the last quarter. Finally, Nebula Research & Development LLC bought a new position in shares of Urogen Pharma during the second quarter valued at $162,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Price Performance

NASDAQ:URGN opened at $21.25 on Friday. Urogen Pharma has a one year low of $3.42 and a one year high of $30.00. The business has a fifty day moving average price of $23.74 and a 200-day moving average price of $19.79. The firm has a market capitalization of $994.71 million, a price-to-earnings ratio of -6.14 and a beta of 1.29.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.03. The company had revenue of $27.48 million during the quarter, compared to analysts’ expectations of $34.09 million. On average, equities research analysts expect that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on URGN. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Urogen Pharma in a report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, D. Boral Capital reiterated a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a research note on Monday, January 5th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $33.00.

Insider Transactions at Urogen Pharma

In related news, insider Mark Schoenberg sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the sale, the insider directly owned 139,025 shares of the company’s stock, valued at approximately $3,475,625. This represents a 6.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.70% of the company’s stock.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.